Development and optimization of nanodelivery of novel inhibitors of ERCC 1 /XPF for enhanced cancer therapy
Loading...
Date
Citation for Previous Publication
Link to Related Item
Abstract
Description
This research investigates the potential of using the malaria drug pyronaridine (PYD) and its liposomal formulation (LPY) to sensitize cancer cells to treatment. Specifically, it targets the ERCC1/XPF enzyme complex crucial for DNA repair, making cancer cells more responsive to radiation therapy and platinum-based chemotherapy. Preliminary findings indicate a potential synergistic effect when combining PYD with cisplatin in certain cancer cell lines (FaDu and H1299). However, further research is needed to confirm and compare these effects with free PYD. This approach holds promise for enhancing cancer treatment strategies by inhibiting ERCC1/XPF and enhancing chemotherapy sensitivity.
Item Type
http://purl.org/coar/resource_type/c_6670
Alternative
Other License Text / Link
Subject/Keywords
Language
en